IL-1 binding proteins
AssigneeAbbVie Inc.
InventorsChengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
Life of this patent
Estimating the term…
Abstract
Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.
Claims18
A method for reducing human IL-1 activity in a human subject in need thereof, comprising administering to the human subject a binding protein, wherein the binding protein comprises first and second polypeptide chains, wherein said first polypeptide chain comprises a first VD1-(X1)n-VD2-C-(X2)n, wherein:
- VD1 is a first heavy chain variable domain;
- VD2 is a second heavy chain variable domain;
- C is a heavy chain constant domain;
- X1 is a linker with the proviso that it is not CH1;
- X2 is an Fc region;
- and
- n is independently 0 or 1;
- and
- wherein said second polypeptide chain comprises a second VD1-(X1)n-VD2-C-(X2)n,
- wherein:
- VD1 is a first light chain variable domain;
- VD2 is a second light chain variable domain;
- C is a light chain constant domain;
- X1 is a linker with the proviso that it is not CH1;
- X2 does not comprise an Fc region;
- and
- n is independently 0 or 1;
- wherein, in said first polypeptide chain, VD1 comprises the amino acid sequence of SEQ ID NO:
- 204;
- and VD2 comprises the amino acid sequence of SEQ ID NO:
- 213;
- wherein, in said second polypeptide chain, VD1 comprises the amino acid sequence of SEQ ID NO:
- 238;
- and VD2 comprises the amino acid sequence of SEQ ID NO:
- 216;
- and
- wherein the binding protein binds human IL-1β and human IL-la, such that the human IL-1 activity in the human subject is reduced.
A method for reducing human IL-1 activity in a human subject in need thereof, comprising administering to the human subject a binding protein, wherein the binding protein comprises first and second polypeptide chains, wherein said first polypeptide chain comprises a first VD1-(X1)n-VD2-C-(X2)n, wherein:
- VD1 is a first heavy chain variable domain;
- VD2 is a second heavy chain variable domain;
- C is a heavy chain constant domain;
- X1 is a linker with the proviso that it is not CH1;
- X2 is an Fc region;
- and
- n is independently 0 or 1;
- and
- wherein said second polypeptide chain comprises a second VD1-(X1)n-VD2-C-(X2)n,
- wherein:
- VD1 is a first light chain variable domain;
- VD2 is a second light chain variable domain;
- C is a light chain constant domain;
- X1 is a linker with the proviso that it is not CH1;
- X2 does not comprise an Fc region;
- and
- n is independently 0 or 1;
- wherein said first polypeptide chain comprises the amino acid sequence of SEQ ID NO:
- 212;
- wherein said second polypeptide chain comprises the amino acid sequence of SEQ ID NO:
- 215;
- and
- wherein the binding protein binds human IL-1β and human IL-la, such that the human IL-1 activity is reduced.
Dependencies are inferred from the claim text.